- |||||||||| ACE-2494 / Acceleron
Preclinical, Journal: Novel ActRIIB ligand trap increases muscle mass and improves bone geometry in a mouse model of severe osteogenesis imperfecta. (Pubmed Central) - Oct 25, 2020
However, treatment of Col1a1mice with ACE-2494 was associated with significant gain in muscle mass, significantly improved bone length and bone geometry, but no significant treatment effect was found on bone mass or bone mechanical properties. Thus, our data indicate that activin A/myostatin neutralizing antibody ACE-2494 is effective in stimulating muscle mass, bone length and diaphyseal bone growth but does not correct bone mass phenotype in a mouse model ofdominant OI.
- |||||||||| ACE-2494 / Merck (MSD)
Trial completion, Trial completion date: A Study of ACE-2494 in Healthy Subjects (clinicaltrials.gov) - Jul 17, 2019
P1, N=48, Completed,
Thus, our data indicate that activin A/myostatin neutralizing antibody ACE-2494 is effective in stimulating muscle mass, bone length and diaphyseal bone growth but does not correct bone mass phenotype in a mouse model ofdominant OI. Active, not recruiting --> Completed | Trial completion date: Oct 2019 --> Jun 2019
- |||||||||| ACE-2494 / Merck (MSD)
Trial completion date, Trial primary completion date: A Study of ACE-2494 in Healthy Subjects (clinicaltrials.gov) - Jul 5, 2019
P1, N=48, Active, not recruiting,
Active, not recruiting --> Completed | Trial completion date: Oct 2019 --> Jun 2019 Trial completion date: May 2019 --> Oct 2019 | Trial primary completion date: May 2019 --> Aug 2019
- |||||||||| ACE-2494 / Merck (MSD)
Enrollment closed: A Study of ACE-2494 in Healthy Subjects (clinicaltrials.gov) - Apr 5, 2019
P1, N=48, Active, not recruiting,
Trial completion date: May 2019 --> Oct 2019 | Trial primary completion date: May 2019 --> Aug 2019 Recruiting --> Active, not recruiting
|
